MRD conversion during oral azacitidine maintenance correlates with outcomes in predominantly favorable-risk AML

Abstract Background Oral azacitidine improves survival in patients with AML in first complete remission who are not candidates for allogeneic transplantation. Most favorable-risk AML patients harbor molecular markers enabling sensitive measurable residual disease (MRD) monitoring. While MRD is a wel...

Descripció completa

Dades bibliogràfiques

Autors principals:	Noa Hurvitz, Irina Amitai, Ilana Levy Yurkovski, Ariella Tvito, Yishai Ofran, Tzvika Porges, Ofir Wolach, Adi Sherban, Noa Gross Even-Zohar, Vladimir Vainstein, Arnon Haran, Shlomzion Aumann, Robert Mikhelashvili, Avraham Frisch, Boaz Nachmias
Format:	Artigo
Idioma:	Inglês
Publicat:	Springer 2026-05-01
Col·lecció:	Annals of Hematology
Matèries:	Acute myeloid leukemia Maintenance Oral azacitidine Measurable residual disease Onureg
Accés en línia:	https://doi.org/10.1007/s00277-026-07054-5
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!